Active substanceSalbutamolSalbutamol Similar drugsTo uncover Astalin aerosol d / inhal. Cipla Ltd. India Ventolin® aerosol d / inhal. GlaxoSmithKline Trading, ZAO Russia Ventolin® Nebulas solution d / inhal. Aspen Pharma Petit Co., Ltd. Russia Salamol Steri-Neb solution d / inhal. AIVEX Pharmaceuticals Yukey Limited United Kingdom Salamol Eco Light Breath aerosol d / inhal. Norton Waterford, acting under the trade name Ivex Pharmaceuticals Ireland Ireland Salbutabs pills inwards NATIVA, LLC Russia Salbutamol aerosol d / inhal. MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia Salbutamol aerosol d / inhal. ALVILS, LTD. Russia Salbutamol aerosol d / inhal. BINNOFARM, CJSC Russia Salbutamol AB aerosol d / inhal. ALTAYVITAMINS, CJSC Russia Salbutamol aeronaut aerosol d / inhal. NATIVA, LLC Russia Salbutamol-MCPP aerosol d / inhal. MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia Salbutamol-native solution d / inhal. NATIVA, LLC Russia Salbutamol-SOLOfarm solution d / inhal. GROTEKS, LLC Russia Salbutamol-Teva aerosol d / inhal. Teva Pharmaceutical Enterprises Co., Ltd. Israel Salgim® powder d / inhal. PULMOMED, CJSC Russia Saltos® pills inwards PULMOMED, CJSC Russia Cibutocaps Cibutocaps capsules d / inhal. Teva Pharmaceutical Enterprises Co., Ltd. Israel Dosage form: & nbspThe tablets of the prolonged action, covered with a cover. Composition:Active substance: salbutamol hemisuccinate 7.23 mg (6 mg in terms of salbutamol).Excipients: sodium chloride 111.72 mg, povidone 2.6 mg, carmellose sodium 2.6 mg, magnesium stearate 1.25 mg.Sheath composition: cellulose acetate 4.43 mg, dibutyl phthalate 0.17 mg. Description:White or almost white biconvex tablets covered with a semipermeable membrane with a calibrated orifice. On fracture white or almost white. Pharmacotherapeutic group:Bronchodilator - beta2-adrenomimetic is selective. ATX: & nbspR.03.A.C Selective beta-2-adrenomimeticsR.03.A.C.02 Salbutamol Pharmacodynamics:Bronchodilator. In therapeutic doses has a pronounced stimulating effect on beta2-adrenoreceptors of bronchi, blood vessels and myometrium. Virtually no effect on beta 1-adrenoreceptors of the heart.May cause desensitization and a decrease in the number of beta2-adrenergic receptors, incl. on lymphocytes. It has a number of metabolic effects: reduces the potassium content in the plasma, affects glycogenolysis and insulin secretion, has a hyperglycemic and lipolytic effect, increases the risk of acidosis.In recommended therapeutic doses does not have a negative effect on the cardiovascular system, does not cause an increase in blood pressure. To a lesser degree, in comparison with the drugs of this group, it has a positive chrono- and inotropic effect. Causes the enlargement of the coronary arteries. It has a tocolytic effect: it lowers the tone and contractile activity of the myometrium.Prevents the development of bronchospasm, improves breathing against the background of developed bronchospasm, prevents night attacks of suffocation.Controlled release of salbutamol hemisuccinate after taking the tablet inside allows the creation and long-term maintenance of an effective therapeutic concentration in the blood. The therapeutic effect persists for 12-14 hours. Pharmacokinetics:It is well absorbed in the gastrointestinal tract. The half-life is 6 hours. It is subjected to the systemic metabolism in the liver and in the intestinal wall. Connection with plasma proteins - 10%. It is excreted by the kidneys (69-90%), mainly in unchanged form and in the form of an inactive phenol sulfate metabolite (60%) and bile (4%). Indications:Bronchospastic syndrome, bronchial asthma (including nocturnal) chronic obstructive pulmonary disease, chronic bronchitis, emphysema. Contraindications:Hypersensitivity to the components of the drug, ischemic heart disease, severe heart failure, arrhythmia (paroxysmal tachycardia, polytopic ventricular extrasystole); myocarditis, heart defects, aortic stenosis, decompensated diabetes mellitus, hyperthyroidism, pheochromocytoma, glaucoma, epicentricles, pyloroduodenal stenosis, kidney and liver diseases with violation of their function, the first trimester of pregnancy, simultaneous reception of non-selective beta-blockers. Children under 12 years. Carefully:Chronic heart failure of mild and moderate degree, arterial hypertension, pheochromocytoma. Pregnancy and lactation:The purpose of the drug is rational if the use of its use for the mother exceeds the potential risk to the fetus or child. Care must be taken because it can cause tachycardia and hyperglycemia in the mother (especially if there is diabetes) and the fetus, and cause the mother to delay the labor. Because the salbutamol penetrates into breast milk, its use during the period of breastfeeding is possible only if the expected therapeutic effect for the mother exceeds the potential risk for the child. Dosing and Administration:Orally. Adults and children over 12 years - one tablet 7.23 mg once a day in the afternoon. The maximum daily dose of 4 tablets (24 mg of salbutamol).The tablet should be swallowed whole, without chewing. Side effects:Often - palpitation, tachycardia (in pregnancy - in the mother and fetus), headache, distal tremor, nervous tension. Less often - dizziness, insomnia, muscle cramps, nausea, vomiting, excessive sweating. Rarely - allergic reactions - urticaria, skin rash, angioedema, paradoxical bronchospasm, erythema multiforme, Stevens-Johnson syndrome, arrhythmia, chest pain, hypokalemia, psychoneurological disorders, incl. psychomotor agitation, disorientation, sleep disturbance, memory impairment, aggressiveness, panic state, hallucinations, suicidal attempts, schizophreniform disorders, urinary retention. Overdose:Symptoms of acute poisoning: angina, tachycardia, palpitation, arrhythmia, dizziness dryness of the oral mucosa, fatigue, headache, hyperglycemia (replacing hypoglycemia), decreased or increased blood pressure, hypokalemia, insomnia, malaise, nausea, nervous tension, convulsions, tremor .Treatment: drug withdrawal, gastric lavage and symptomatic therapy (use of selective beta-1 blockers requires caution in patients with bronchial asthma due to the risk of developing severe bronchospasm). Interaction:Theophylline and other xanthines with simultaneous application increase the likelihood of developing tachyarrhythmias; means for inhalation anesthesia, levodopa Severe ventricular arrhythmias.Monoamine oxidase inhibitors and tricyclic antidepressants increase the effect of salbutamol, which can lead to a sharp drop in blood pressure.It is not recommended simultaneous use of salbutamol and nonselective beta-blockers (such as propranolol) because of the danger of developing severe bronchospasm.Administration with anticholinergics can help increase eye pressure.Diuretics and glucocorticosteroids increase the hypokalemic effect of salbutamol.Enhances the effect of stimulants of the central nervous system, a side effect on the heart of the thyroid hormones.Increases the likelihood of glirocidal intoxication.Reduces the antianginal effectiveness of nitrates and hypotensive activity of antihypertensive drugs. Special instructions:Frequent use of salbutamol can lead to an increase in bronchospasm, sudden death, and therefore between the doses of regular doses of the drug should take breaks in a few hours (6 hours). Reduction of these intervals can occur only in exceptional cases. The use of salbutamol, as a rule, does not adversely affect the ability to drive vehicles and other activities that require special attention and quick reactions. Nevertheless, the question of the possibility of driving a vehicle should be addressed after assessing the individual tolerability of the drug.Tablets with a damaged shell or broken are not suitable for use. Form release / dosage:The tablets of the prolonged action, covered with a cover of 7,23 mg. Packaging:30 tablets in a plastic vial. A bottle with instructions in a pack of cardboard. Storage conditions:In a dry, protected from light place, at a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:4 years. Do not use after the date shown on the package. Terms of leave from pharmacies:On prescription Registration number:P N002277 / 01 Date of registration:23.06.2008 / 26.11.2014 Expiration Date:Unlimited The owner of the registration certificate:NATIVA, LLC NATIVA, LLC Russia Manufacturer: & nbspNATIVA, LLC Russia Information update date: & nbsp2016-09-15 Illustrated instructions × Illustrated instructions Instructions